Skip to main content

Table 2 Univariate and multivariate analysis of disease free survival and overall survival

From: Relationships between serum HER2 ECD, TIMP-1 and clinical outcomes in Taiwanese breast cancer

Variables

Disease-free survival

Overall survival

 

p value

 

p value

 
 

Univariate

Multivariate

HR a (95% CI)

Univariate

Multivariate

HR a (95% CI)

Age

0.037

0.205b

1.53 (0.79 - 2.96)b

0.138

  
  

0.278c

1.44 (0.75 - 2.78)c

   

Tumor size

0.862

  

0.563

  

Lymph node

0.003

0.003b

2.70 (1.40 - 5.23)b

0.002

0.002b

2.81 (1.46 - 5.42)b

  

0.008c

2.41 (1.25 - 4.64)c

 

0.005c

2.57 (1.34 - 4.93)c

ER

0.0008

0.004b

3.79 (1.53 - 9.38)b

0.002

0.004b

3.52 (1.50 - 8.23)b

PR

0.109

  

0.168

  

HER2/neu

0.997

  

0.619

  

Grade

0.183

  

0.318

  

ECD

0.0002

0.214b

1.62 (0.76 - 3.47)b

0.005

0.451b

1.34 (0.62 - 2.90)b

  

0.097c

1.89 (0.89 - 3.99)c

 

0.341c

1.45 (0.68 - 3.09)c

Chemotherapy*

0.122

  

0.224

  

Radiation therapy

0.418

  

0.859

  

Hormone therapy

0.001

0.011c

0.31 (0.13 - 0.77)c

0.001

0.004c

0.27 (0.11 - 0.65)c

  1. * Anthracycline-based regimen (82/185, 44.3%), CMF (cyclophosphamide, methotrexate and 5-fluorouracil) (64/185, 34.6%), taxane (45/185, 24.3%), trastuzumab (22/185, 11.9%), lapatinib (3/185, 1.6%) and others (28/185, 15.1%) were used as the first line adjuvant chemotherapy in this breast cancer cohort.
  2. aAdjusted for other prognostic variables as listed on the left.
  3. b, cSince most patients who were ER positive underwent hormone therapy, ER and hormone therapy were included in the model separately.